Fig. 1 · Structure

Documents & Downloads

ARP 100

Cat. No. A15292 CAS 704888-90-4

MMP-2 inhibitor

ARP 100 is a selective inhibitor of matrix metalloproteinases 2 (MMP-2) with IC50 value of 12 nM.

In Stock

Publications for ARP 100

1 publication citing this product

  1. Wenyuan Xiao, .et al. , Proteoglycan Research, 2026, 4 (2026): 1-12

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

ARP-100 has been used to probe MMP2-associated glypican-4 shedding. In mouse diaphragm endothelial cells, 60 nM ARP100 for 6 h reduced GPC4 detected in conditioned medium relative to control. This cellular result does not establish an enzyme IC50 or exclusive MMP-2 selectivity. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
MMP-2 IC50 12 nM
MMP-9 IC50 0.2 μM
MMP-3 IC50 4.5 μM
MMP-1 IC50 >50 μM
MMP-7 IC50 >50 μM

In Vitro Studies

ARP-100 produced concentration-dependent changes in flow-driven HUVEC networks. At 10 μM, vessels became narrower while retaining perfusability; 20 μM yielded nonperfusable networks, and 50 μM disrupted network formation. These findings apply to the tested fibrin-based vascular model. [2]

ARP100 reduces GPC4 shedding in diaphragm endothelial cells

Cell-based study · Immortalized mouse diaphragm endothelial cells (dECs) [1]

ARP100 reduced shed GPC4 detected in conditioned medium relative to control. This is a cellular substrate-shedding result, not an enzyme IC50 determination.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
GPC4 in conditioned mediumReported qualitative response Reduced versus control; *P < 0.05[1]

Literature-Reported Treatment Conditions

Treatment concentration
60 nM
Exposure duration
6 h
Method
Treatment in serum-free DMEM following 6 h starvation; conditioned-medium Western blot
Reported limits
ARP100 solvent and solvent fraction in the Figure 4D control are not specified in the read methods. Exact effect size and explicit replicate definition are not adopted.
Methods and source locations

Compound reported in the paper: ARP-100; Compound label in the paper: ARP100

Reported compound and model only; no salt conversion, exclusive supplier attribution or validation of the current Adooq lot.

Figure 4D image/caption; Results: MMP2 specifically cleaves Glypican4; Reagents, Cell lines, conditioned-media and Western blot methods

GPC4 in conditioned medium: Western blot with N-terminal GPC4 antibody. Figure 4 caption: mean ± SEM, Student’s t-test. — Figure 4D image/caption; Results: MMP2 specifically cleaves Glypican4; Reagents, Cell lines, conditioned-media and Western blot methods

Concentration-dependent remodeling of flow-driven HUVEC networks

Cell-based study · GFP-labeled HUVEC monocultures in fibrin within a single-channel microfluidic device; interstitial flow driven by a 10 mm H2O pressure difference [2]

ARP-100 altered vascular morphology and perfusability. At 10 μM vessels were narrower but remained perfusable; 20 μM produced nonperfusable narrow networks, and 50 μM prevented connected network formation. These high micromolar responses do not establish exclusive MMP-2 dependence.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Morphology and perfusability at 10 μMReported qualitative response Narrower vessels, lower coverage and more branches; perfusability maintained[2]
Vascular network formation at 20 μMReported qualitative response Extremely narrow vessels; not perfusable[2]
Vascular network formation at 50 μMReported qualitative response Most cells remained disconnected at day 5; network formation failed[2]

Literature-Reported Treatment Conditions

Treatment concentration
10, 20 or 50 μM
Exposure duration
Throughout network formation; day-5 failure described for 50 μM
Method
Added to culture medium under interstitial flow
Vehicle
DMSO control; final fraction not specified
Reported limits
No exact common imaging day is assigned to all Figure 5 panels; general culture duration is 5–7 days. Exclusive target selectivity at these concentrations was not demonstrated.
Methods and source locations

Compound reported in the paper: ARP-100; Compound label in the paper: ARP-100

Reported compound and model only; no salt conversion, exclusive supplier attribution or validation of the current Adooq lot.

Results 2.4–2.5; Figures 4e and 5a–e images/captions; Methods: cell culture, network formation, inhibitor treatment, perfusion/imaging and Statistics

Morphology and perfusability at 10 μM: Confocal GFP/40 kDa Texas Red dextran imaging. Perfusability = projected dextran-positive area / GFP-positive vessel area. Control n=5 devices; inhibitor groups n=3 devices; mean ± SD; t-tests. — Results 2.5; Figure 5a–e; perfusion/imaging methods; Statistics

Vascular network formation at 20 μM: GFP/dextran confocal imaging versus DMSO control; no decimal effect sizes inferred. — Results 2.4; Figure 4e; Figure 5a–e

Vascular network formation at 50 μM: GFP/dextran confocal imaging versus DMSO control. — Results 2.4; Figure 4e; Figure 5a

In Vivo Studies

In a rat chronic constriction injury model, intrathecal ARP-100 (10 nmol daily on post-injury days 1–7) increased paw withdrawal threshold and latency versus vehicle on days 3 and 7. The study did not establish sustained benefit at days 14 or 21. [3]

Transient behavioral response to ARP-100 after nerve injury

Animal study · Adult male Sprague–Dawley rats (250–300 g), CCI model [3]

ARP-100 increased mechanical paw withdrawal threshold and thermal withdrawal latency versus vehicle-treated CCI rats at days 3 and 7. Sustained benefit at days 14 or 21 was not established.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Mechanical withdrawal threshold and thermal withdrawal latencyReported qualitative response Increased on days 3 and 7 versus CCI + 10% DMSO; *P < 0.05[3]

Conditions shared by the study groups

Route
Intrathecal, lumbosacral cerebrospinal fluid space
Frequency
Daily for 7 consecutive days (Protocol IV)
Treatment course
Post-CCI days 1–7; behavioral follow-up through day 21
Vehicle
10% DMSO comparator (10 μL); drug stock described as 1 nmol/μL in DMSO
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
CCI + ARP-100
10 nmol per administration
Sham; CCI; CCI + 10% DMSO. Protocol IV specifies n=5 rats per behavioral group.Paw withdrawal threshold and latency increased versus CCI + 10% DMSO on days 3 and 7 (*P < 0.05); later time points lack significance annotations for this comparison.[3]
CCI + ARP-100
Model: Adult male Sprague–Dawley rats (250–300 g), chronic constriction injury (CCI)
Reported limits: Final drug injectate DMSO percentage is not explicitly reconciled with the stock description. No exact means are taken from curves.
Methods and source locations

Compound reported in the paper: ARP-100; Compound label in the paper: MMP-2 inhibitor III (compound 10a)

Reported compound and model only; no salt conversion, exclusive supplier attribution or validation of the current Adooq lot.

Methods: Animals, Drugs and administration, Protocol IV, behavioral assays, Statistical analysis; Figure 6F full-size image/caption

Mechanical withdrawal threshold and thermal withdrawal latency: von Frey and hot-plate tests; baseline and post-CCI days 1, 3, 7, 14, 21. n=5 rats/group; mean ± SEM; Methods specify one- or two-way ANOVA with Bonferroni post hoc comparisons. — Methods: Animals, Drugs and administration, Protocol IV, behavioral assays, Statistical analysis; Figure 6F full-size image/caption

CCI + ARP-100 · Methods: Animals, Drugs and administration, Protocol IV, behavioral assays, Statistical analysis; Figure 6F full-size image/caption

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 704888-90-4
Applications MMP-2 inhibitor
Formula C17H20N2O5S
Molecular Weight 364.42
SMILES
CC(C)ON(CC(=O)NO)S(=O)(=O)C1=CC=C(C=C1)C2=CC=CC=C2

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Wenyuan Xiao, Alexander R Orta, Jingwen Yue, et al. MMP2 sheds Glypican-4 to suppress Slit3-Robo4 signaling and angiogenesis Proteoglycan research (2026). PMID: 42610126 DOI: 10.1002/pgr2.70044 Source material
  2. [2] Shun Zhang, Zhengpeng Wan, Georgios Pavlou, et al. Interstitial flow promotes the formation of functional microvascular networks in vitro through upregulation of matrix metalloproteinase-2 Advanced functional materials (2022). PMID: 36569597 DOI: 10.1002/adfm.202206767 Source material
  3. [3] Wang, Chenglong, Xu, Yitong, Xu, Miao, et al. SPOCK2 modulates neuropathic pain by interacting with MT1-MMP to regulate astrocytic MMP-2 activation in rats with chronic constriction injury Journal of Neuroinflammation (2024). PMID: 38388415 DOI: 10.1186/s12974-024-03051-5 Source material

Publications

1 publication citing this product

  1. Wenyuan Xiao, .et al. , Proteoglycan Research, 2026, 4 (2026): 1-12

Added to your cart

View Cart Checkout
Loading...